List of Excipients in Branded Drug GAMASTAN

Gamastan Excipient Strategy, FDA Status, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Gamastan is a plasma-derived human immune globulin for intramuscular administration. Its formulation uses a narrow excipient system centered on glycine, sodium chloride, and water for injection. Commercial opportunities are strongest in supply security, excipient optimization, ready-to-use passive immunization products, and regional manufacturing partnerships rather than in conventional generic substitution.

The product’s principal constraints are biological variability, plasma supply, immunoglobulin aggregation risk, intramuscular volume limits, and the regulatory burden associated with changes to a licensed plasma-derived product.

What is Gamastan and what excipients does it contain?

Gamastan S/D is a sterile solution of human immune globulin for intramuscular injection. The active substance is predominantly immunoglobulin G derived from human plasma. The product label describes a protein concentration of approximately 15% to 18%, with at least 96% of the protein represented by IgG.[1]

Product attribute	Gamastan S/D profile
Active ingredient	Immune globulin human
Dosage form	Sterile solution for intramuscular injection
Administration	Intramuscular
Protein concentration	Approximately 15% to 18%
Principal antibody class	IgG
Stabilizing excipient	Glycine
Tonicity agent	Sodium chloride
Vehicle	Water for injection
Preservative	No preservative identified in the U.S. labeling
Container system	Single-dose presentation
Product category	Plasma-derived biologic
U.S. regulatory pathway	Biologics license application, not an ANDA

The formulation is deliberately simple. Glycine functions primarily as a stabilizer, while sodium chloride contributes to isotonicity. Water for injection provides the vehicle. A low-excipient formulation reduces the risk of injection-site reactions, excipient-mediated immunogenicity, and interactions with the heterogeneous antibody population present in plasma-derived immune globulin.

The U.S. prescribing information identifies hepatitis A, measles, varicella, and other exposure-related passive immunization uses among the product’s clinical applications, subject to the applicable indication and dosing instructions.[1]

How strong is the Gamastan formulation and excipient strategy?

Gamastan’s excipient strategy is commercially conservative and technically defensible. It relies on excipients with established parenteral use and avoids preservatives that could create additional tolerability concerns in a product administered to children, pregnant patients, and immunocompromised individuals.

Glycine as the primary stabilizer

Glycine is commonly used in immunoglobulin formulations because it can support protein stability without introducing a surfactant or complex buffer system. Its use may help limit conformational instability and aggregation during storage.

The commercial limitation is that glycine alone provides less formulation flexibility than systems that combine amino acids, sugars, surfactants, or proprietary buffering agents. A competing product could seek improved stability through:

• Lower aggregate formation during long-term storage
• Greater resistance to temperature excursions
• Improved recovery after transport
• Reduced visible or subvisible particles
• Longer in-use stability after vial opening
• Better compatibility with prefilled syringes or autoinjectors

Any change would require a full comparability assessment because the active material is a heterogeneous antibody population derived from human plasma.

Sodium chloride and injection-site tolerability

Sodium chloride supports isotonicity but contributes to the overall ionic strength of the formulation. An alternative tonicity strategy could use a different salt concentration, sorbitol, sucrose, or another approved tonicity modifier. The commercial value of such a change would depend on whether it reduces pain, swelling, or local reactions without compromising protein stability.

For an intramuscular product, an excipient change that permits a smaller injection volume could have more commercial value than a modest improvement in shelf life. Intramuscular dosing is constrained by muscle volume and patient comfort, particularly in pediatric use.

Preservative-free positioning

The absence of a preservative supports single-dose use and may simplify pediatric and immunocompromised-patient positioning. A multi-dose presentation could reduce packaging cost, but it would create sterility, antimicrobial-preservation, and dosing-control issues. A preservative-free product in a prefilled, single-use device is more commercially aligned with current risk-management expectations than a multi-dose vial.

What formulation patents protect Gamastan?

Public product materials identify Gamastan as a plasma-derived immune globulin product, but they do not establish a current, product-specific formulation patent estate that would block excipient competition.

The principal protection is regulatory and manufacturing-based rather than an obvious active patent barrier. Relevant protection may arise from:

• Plasma sourcing and donor-screening systems
• Viral inactivation and removal processes
• Fractionation and purification methods
• Manufacturing specifications
• Container-closure systems
• Trade secrets covering process controls
• Regulatory exclusivity associated with the biologics license

The U.S. Orange Book generally lists approved drug products with patent and regulatory information submitted under the applicable drug-approval framework. Plasma-derived biologics such as Gamastan are regulated through the biologics framework and should not be analyzed as conventional small-molecule Orange Book products.[2] The Purple Book is the more relevant FDA reference for licensed biological products and biosimilar or interchangeable-product information.[3]

No reliable conclusion can be drawn from an Orange Book search alone about freedom to operate for a competing immune globulin.

Are there Gamastan Paragraph IV challenges?

A conventional Paragraph IV ANDA challenge is not the expected pathway for Gamastan because Gamastan is a biologic product rather than a standard small-molecule drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act.

A competing manufacturer would more likely pursue:

1. A separate biologics license application.
2. A biosimilar application under section 351(k), if the product and reference-product framework support that pathway.
3. A full biologics application where biosimilarity cannot be established.
4. A contract-manufacturing or regional licensing arrangement.
5. A competing immune globulin product with distinct labeling or formulation.

No publicly identified Paragraph IV litigation should be treated as the principal entry risk for Gamastan.

When does Gamastan lose exclusivity?

Gamastan has been marketed for many years, so any statutory exclusivity associated with its original approval has long expired. The product’s practical market protection does not depend on a remaining 12-year reference-product exclusivity period.

For a legacy plasma-derived biologic, entry barriers are more likely to include:

• Access to qualified human plasma
• Donor recruitment and retention
• Fractionation capacity
• Viral safety validation
• Lot-release testing
• Potency and identity testing
• Manufacturing scale
• Regulatory comparability
• Distribution reliability

The absence of a remaining statutory exclusivity period does not mean that a competitor can launch an interchangeable substitute through an abbreviated generic pathway. A new entrant must still obtain FDA authorization and demonstrate product quality, safety, and efficacy under the appropriate biologics pathway.

What is the FDA and Orange Book status of Gamastan?

Gamastan is an FDA-regulated human immune globulin product marketed under a biologics license. Its regulatory status should be reviewed through FDA biologics records, the product prescribing information, and the manufacturer’s current labeling rather than through an ordinary generic-drug framework.[1,3]

Regulatory question	Gamastan assessment
FDA-approved product?	Yes, as a licensed human immune globulin biologic
ANDA product?	No
Standard Orange Book patent listing?	Not the primary regulatory reference
Purple Book relevance	Yes, for licensed biologic and biosimilar analysis
Biosimilar competition	Legally possible in principle, but technically demanding
Interchangeable designation	No identified interchangeable substitute in the cited public materials
Prescription status	Prescription biologic
Preservative-free status	Product labeling identifies no preservative

The product label remains the controlling source for indications, contraindications, warnings, storage, dosage, and administration. Distribution and availability can change independently of FDA approval status.

What commercial opportunities exist in Gamastan excipients?

The most credible opportunities are incremental formulation and delivery improvements rather than a direct excipient replacement.

1. Improved thermal stability

A formulation that maintains IgG monomer content and potency under controlled temperature excursions could reduce product losses in international distribution. Potential approaches include alternative amino-acid stabilizers, sugar-based stabilizers, or carefully selected surfactants.

The development program would need to evaluate:

• Monomer and aggregate content
• Fragmentation
• Antibody subclass distribution
• Anti-complementary activity
• Particulate burden
• Potency across relevant antibody assays
• Container-closure compatibility
• Accelerated and real-time stability

2. Lower injection volume

A higher-concentration intramuscular product could reduce injection volume, but concentration increases may affect viscosity, protein-protein interactions, aggregation, and injection force. The commercial opportunity is significant because dosing is based on body weight and may require substantial volumes in adults.

The technical risk is that increasing protein concentration without changing the administration route may worsen local tolerability. A viable product would need to establish a balance among concentration, viscosity, injection force, pain, and local reaction rates.

3. Prefilled syringe or wearable delivery

A prefilled syringe could reduce preparation steps and dosing errors. A wearable or automated injector is less straightforward because intramuscular delivery requires reliable needle placement and adequate delivery into muscle tissue.

Device development would need to address:

• High-protein solution viscosity
• Needle gauge
• Injection time
• Silicone-oil interaction
• Extractables and leachables
• Dose accuracy
• Cold-chain handling
• Human factors

4. Pediatric-friendly delivery

Gamastan’s use in exposure-related prophylaxis creates an opportunity for lower-volume, lower-pain delivery. A pediatric presentation could use a smaller dose, improved injection device, or packaging that simplifies weight-based calculation.

The product cannot be materially repositioned solely through packaging. Any change that affects dose concentration, route, or patient population would require regulatory review.

5. Regional fill-finish and licensing

Regional partnerships may create more value than an independent excipient program. A manufacturer with plasma access but limited finished-product capacity could license:

• Formulation know-how
• Fill-finish technology
• Container systems
• Stability data
• Analytical methods
• Regulatory dossiers
• Cold-chain distribution rights

The commercial case depends on securing plasma supply and demonstrating consistent product quality. An excipient license without access to qualified plasma or fractionation capacity has limited standalone value.

How does Gamastan compare with competing immune globulin products?

Gamastan competes with other human immune globulin products, but the products are not automatically substitutable. Differences in concentration, stabilizer, route, indication, dosage, antibody content, and administration setting are commercially important.

Factor	Gamastan	Potential competing immune globulin
Route	Intramuscular	Intramuscular, subcutaneous, or intravenous
Formulation	Glycine, sodium chloride, water for injection	May use glycine, sugars, amino acids, surfactants, or other systems
Primary use	Passive immunization after specific exposures	Broader prophylactic or replacement indications depending on product
Substitution	Requires clinical and regulatory assessment	Not automatically interchangeable
Main differentiation	Established IM presentation and simple formulation	Volume, route, stability, supply, device, or price
Manufacturing barrier	Human plasma-derived production	Same if plasma-derived

A subcutaneous immune globulin cannot be assumed to replace an intramuscular exposure-prophylaxis product. The clinical indication, pharmacokinetics, dose, and regulatory labeling must align.

What patent litigation and settlement risks affect Gamastan?

The main legal risks are unlikely to center on a single formulation patent. They are more likely to involve:

• Process patents for plasma fractionation
• Viral inactivation methods
• Purification and filtration
• Analytical testing
• Device and container systems
• Trade-secret misappropriation
• Supply and licensing agreements
• Product liability and manufacturing quality

No publicly established Gamastan-specific Paragraph IV settlement is identified in the cited regulatory materials. A biosimilar or competing biologic could still face patent litigation under the Biologics Price Competition and Innovation Act if the reference-product sponsor asserts patents during the biosimilar information-exchange process.[4]

What generic launch scenarios exist for Gamastan?

Scenario 1: Direct generic entry

This is the least likely scenario. Gamastan is not a conventional small-molecule product suited to an ANDA-based generic launch.

Scenario 2: Biosimilar immune globulin

A biosimilar applicant would need to demonstrate high similarity despite the inherent variability of plasma-derived products. The applicant would also need a robust analytical package and clinical justification for the proposed indications.

Scenario 3: Full biologics application

A competitor could develop a separate human immune globulin product and pursue a full BLA. This route would require substantial manufacturing, clinical, analytical, and regulatory investment.

Scenario 4: Regional licensed competitor

A manufacturer could enter through a supply, co-development, or licensing agreement with an established plasma fractionator. This may be the most commercially realistic route in markets where Gamastan availability is constrained.

How strong is the commercial opportunity?

The opportunity is moderate for formulation and delivery improvements and high for dependable supply in underserved markets. It is weaker for a simple excipient substitution because Gamastan’s current formulation is already concise, established, and compatible with intramuscular use.

Revenue exposure cannot be calculated reliably from public product labeling alone. The relevant commercial metrics are:

• Annual unit volume
• Average selling price
• Hospital and government-contract share
• Geographic sales
• Product allocation during shortages
• Gross margin after plasma and manufacturing costs
• Share of sales from exposure-prophylaxis indications
• Cost of regulatory supplements for formulation changes

The highest-value product concept would combine stable supply, reduced injection volume, pediatric usability, and validated temperature robustness. An excipient change that delivers only a small shelf-life benefit would have a weaker return profile.

Key Takeaways

• Gamastan is a plasma-derived human immune globulin for intramuscular use.
• Its principal excipients are glycine, sodium chloride, and water for injection.
• The formulation has a low-complexity excipient profile and no identified preservative.
• Gamastan should be analyzed under the biologics framework, not as a conventional Orange Book generic.
• Paragraph IV litigation is not the expected generic-entry mechanism.
• The principal barriers are plasma supply, manufacturing, viral safety, comparability, and regulatory approval.
• Commercial opportunities include thermal-stability improvement, lower injection volume, pediatric delivery, prefilled presentation, and regional licensing.
• A direct excipient substitution is less attractive than an integrated formulation-and-device program.
• No product-specific active patent barrier or Gamastan-specific Paragraph IV settlement is established by the cited public sources.

FAQs

Can Gamastan be reformulated with sucrose instead of glycine?

Potentially, but the change would require extensive stability, comparability, safety, and regulatory evaluation. Glycine is part of the established product formulation, and sucrose could alter viscosity, osmolality, aggregation behavior, and container compatibility.

Is Gamastan interchangeable with intravenous immune globulin?

No automatic interchangeability exists. Route, indication, dose, antibody content, pharmacokinetics, and labeling differ among immune globulin products.

Could a biosimilar company use Gamastan as its reference product?

A company could assess Gamastan under the applicable biologics pathway, but biosimilarity to a heterogeneous plasma-derived product would require a substantial analytical and regulatory program. Reference-product eligibility and FDA requirements must be evaluated at the time of application.

Would a higher-concentration Gamastan reduce the number of injections?

It could reduce volume, but not necessarily the number of injection sites. Higher concentration can increase viscosity, injection force, local reactions, and aggregation risk.

Is glycine a strong differentiator for Gamastan?

Glycine is a useful formulation element but is not, by itself, a strong commercial barrier. Differentiation would be more defensible through the complete formulation, manufacturing process, analytical controls, stability package, and delivery system.

References

1. Grifols Therapeutics LLC. (2024). Gamastan S/D: Immune globulin human injection, solution prescribing information. U.S. Food and Drug Administration/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2024). The Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars/biologics-price-competition-and-innovation-act-2009